Diffuse large B cell lymphoma expressing the natural killer cell marker CD56
Toru Sekita
First Department of Pathology, School of Medicine, Chiba University, Chiba,
Search for more papers by this authorJun-ichi Tamaru
First Department of Pathology, School of Medicine, Chiba University, Chiba,
Department of Pathology, Saitama Medical Center, Saitama Medical School, Kawagoe, Japan
Search for more papers by this authorKouichi Isobe
First Department of Pathology, School of Medicine, Chiba University, Chiba,
Search for more papers by this authorKenichi Harigaya
First Department of Pathology, School of Medicine, Chiba University, Chiba,
Search for more papers by this authorSyu-ichi Masuoka
Department of General Internal Medicine, Kashiwa Hospital, Jikei University, School of Medicine, Kashiwa and
Search for more papers by this authorToshio Katayama
Department of General Internal Medicine, Kashiwa Hospital, Jikei University, School of Medicine, Kashiwa and
Search for more papers by this authorMasayuki Kobayashi
Department of General Internal Medicine, Kashiwa Hospital, Jikei University, School of Medicine, Kashiwa and
Search for more papers by this authorAtsuo Mikata
First Department of Pathology, School of Medicine, Chiba University, Chiba,
Department of Pathology, Saitama Medical Center, Saitama Medical School, Kawagoe, Japan
Search for more papers by this authorToru Sekita
First Department of Pathology, School of Medicine, Chiba University, Chiba,
Search for more papers by this authorJun-ichi Tamaru
First Department of Pathology, School of Medicine, Chiba University, Chiba,
Department of Pathology, Saitama Medical Center, Saitama Medical School, Kawagoe, Japan
Search for more papers by this authorKouichi Isobe
First Department of Pathology, School of Medicine, Chiba University, Chiba,
Search for more papers by this authorKenichi Harigaya
First Department of Pathology, School of Medicine, Chiba University, Chiba,
Search for more papers by this authorSyu-ichi Masuoka
Department of General Internal Medicine, Kashiwa Hospital, Jikei University, School of Medicine, Kashiwa and
Search for more papers by this authorToshio Katayama
Department of General Internal Medicine, Kashiwa Hospital, Jikei University, School of Medicine, Kashiwa and
Search for more papers by this authorMasayuki Kobayashi
Department of General Internal Medicine, Kashiwa Hospital, Jikei University, School of Medicine, Kashiwa and
Search for more papers by this authorAtsuo Mikata
First Department of Pathology, School of Medicine, Chiba University, Chiba,
Department of Pathology, Saitama Medical Center, Saitama Medical School, Kawagoe, Japan
Search for more papers by this authorAbstract
The expression of the natural killer (NK) cell antigen, CD56, in hematological malignancies is rare. However, there are several reports that some hematological malignancies, such as T/NK cell lymphoma, multiple myeloma (MM) and acute myeloid leukemia (AML), express this molecule. In B cell non-Hodgkin’s lymphomas (NHL), however, very limited number of cases have been reported to express CD56 molecule. Although one study has recently described that half of microvillous B cell lymphoma (MVL), an uncommon subset of large cell lymphoma, expressed CD56, there have been no reports about most common type of B-NHL, diffuse large B cell lymphoma (DLBL) other than a mention of weak CD56 expression in one of 83 DLBL. We herein presented the first case of diffuse large B cell lymphoma expressing CD56 clearly. The immunophenotype determined by immunostaining and flow cytometric analysis was CD10+, CD19+, CD20+, CD45RO−, CD3− and CD56+. On immunohistochemical study, neither bcl-2 nor TIA-1 was positive for tumor cell. Monoclonal immunoglobulin heavy chain (IgH) gene rearrangement was detected, and the sequence analysis of the variable region of IgH (VH) suggested that this tumor was derived from antigen selected post germinal center B cell. Conventional combination chemotherapy (CHOP) was administered, and the patient has still been in complete remission for 10 months.
REFERENCES
- 1 Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J. Immunol. 1983; 130: 2947 2951.
- 2 Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression of human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 1986; 136: 4480 4486.
- 3 MaClain DA & Edelman GM. A neural cell adhesion molecule from human brain. Proc. Natl Acad. Sci. USA 1982; 79: 6380 6384.
- 4 Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury R, Edelman GM. Neural cell adhesion molecule: Structure, immunoglobulin-like domains, cell surface modula-tion, and alternative RNA splicing. Science 1987; 236: 799 806.
- 5 Maness PF, Beggs HE, Klinz SG, Morse WR. Selective neural cell adhesion molecule signaling by Src family tyrosine kinases and tyrosine phosphatases. Perspectives Dev. Neurobiol. 1996; 4: 169 181.
- 6
Baldwin TJ,
Fazeli MS,
Doherty P,
Walsh FS.
Elucidation of the molecular actions of NCAM and structurally related cell adhesion molecules.
J. Cellular Biochem.
1996; 61: 502 513.
10.1002/(SICI)1097-4644(19960616)61:4<502::AID-JCB3>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 7 Appel F, Holm J, Conscience JF et al. Identification of the border between fibronectin type III homologous repeats 2 and 3 of the neural cell adhesion molecule L1 as a neurite outgrowth promoting and signal transducing domain. J. Neurobiol. 1995; 28: 297 312.
- 8 Van Camp B, Durie BGM, Spier C et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen. Cd56 (Nkh-1; Leu-19). Blood 1990; 76: 377 382.
- 9 Figarella-Branger DF, Durbec PL, Rougon GN. Differential spectrum of expression of neural cell adhesion molecule isoforms and L1 adhesion molecules on human neuroectodermal tumors. Cancer Res. 1990; 50: 6364 6370.
- 10 Moolenaar CECK, Muller EJ, Schol DJ et al. Expression of neural cell adhesion molecule-related sialoglycoprotein in small cell lung cancer and neuroblastoma cell lines H69 and CHP-212. Cancer Res. 1990; 50: 1102 1106.
- 11 Mechtersheimer G, Staudter M, Moller P. Expression of the natural killer cell-associated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors. Cancer Res. 1991; 51: 1300 1307.
- 12 Van Riet I, De Waele M, Remels L, Lacor P, Schots R, Van Camp B. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells. Br. J. Haematol. 1991; 79: 421 427.
- 13 Kern WF, Spier CM, Hanneman EH, Miller TP, Matzner M, Grogan TM. Neural cell adhesion molecule-positive peripheral T-cell lymphoma: A rare variant with a propensity for unusual sites of involvement. Blood 1992; 79: 2432 2437.
- 14 Nakamura S, Suchi T, Koshikawa T et al. Clinicopathologic study of CD56 (NCAM) -positive angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract. Am. J. Surg. Pathol 1995; 19: 284 296.
- 15 DiGiuseppe JA, Louie DC, Williams JE et al. Blastic natural killer cell leukemia/lymphoma: A clinicopathologic study. Am. J. Surg. Pathol. 1997; 21: 1223 1230.
- 16 Suzuki R, Yamamoto K, Seto M et al. CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood 1997; 90: 2417 2428.
- 17 Baer MR, Stewart CC, Lawrence D et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8; 21) (q22; q22). Blood 1997; 90: 1643 1648.
- 18 Paulli M, Boveri E, Rosso R et al. CD56/neural cell adhesion molecule expression in primary extranodal Ki-1/CD30+ lymphoma. Report of a pediatric case with simultaneous cutaneous and bone localizations. Am. J. Dermatopathol. 1997; 19: 384–390.
- 19 Pellat-Deceunynck C, Brille S, Puthier D et al. Adhesion molecules on human myeloma cells: significant changes in expression related to malignancy, tumor spreading, and immortalization. Cancer Res. 1995; 55: 3647 3653.
- 20 Tatsumi T, Shimazaki C, Goto H et al. Expression of Adhesion Molecules on Myeloma Cells. Jpn J. Cancer Res. 1996; 87: 837 842.
- 21 Ng C-S, Lo STH, Chan JKC, Chan WC. CD56+ putative natural killer cell lymphomas: production of cytolytic effecters and related proteins mediating tumor cell apoptosis? Hum. Pathol. 1997; 28: 1276 1282.
- 22 Hammer RD, Vnencak-Jones CL, Manning SS, Glick AD, Kinney MC. Microvillous lymphomas are B-cell neoplasms that frequently express CD56. Mod. Pathol. 1998; 11: 239 246.
- 23 Marks JD, Tristem M, Karpas A, Winter G. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur. J. Immunol. 1991; 21: 985 991.
- 24 Ramasamy I, Brisco M, Morley A. Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrange-ment in B cell neoplasms. J. Clin. Pathol. 1992; 45: 770 775.
- 25 Tamaru J, Hummel M, Zemlin M, Kalvelage B, Stein H. Hodgkin’s disease with a B-cell phenotype often shows a VDJ rearrangement and somatic mutations in the VH genes. Blood 1994; 84: 708 715.
- 26 Hummel M, Tamaru J, Kalvelage B, Stein H. Mantle cell (previously centrocytic) lymphomas express VH genes with no or very little somatic mutations like the physiologic cells of the follicle mantle. Blood 1994; 84: 403 407.
- 27 Osborne BM, Mackay B, Butler JJ, Ordonez NG. Large cell lymphoma with microvillous projections: an ultrastructural study. Am. J. Clin. Pathol. 1983; 79: 443 450.
- 28 Tamaru J, Hummel M, Marafioti T et al. Burkitt’s lymphomas express VH genes with a moderate number of antigen-selected somatic mutations. Am. J. Pathol. 1995; 147: 1398 1407.
- 29 Offit K & Chaganti RSK. Chromosomal aberrations in non-Hodgkin’s lymphoma: Biologic and clinical correlations. Hematol. Oncol. Clin. North Am. 1991; 5: 853 869.
- 30 Offit K, Parsa NZ, Gaidano G et al. 6q deletions define distinct clinicopathologic subsets of non-Hodgkin’s lymphoma. Blood 1993; 82: 2157 2162.
- 31 Gaidano G, Hauptschein RS, Parsa NZ et al. Deletions involving two distinct regions of 6q in B-cell non-Hodgkin’s lymphoma. Blood 1992; 80: 1781 1787.
- 32 Harada H, Kawano M, Huang N et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 1993; 8: 2658 2663.
- 33 Leo R, Boeker M, Peest D et al. Multiparameter analysis of normal and malignant human plasma cells: CD38+, CD56+, CD54+, cIg+ is the common phenotype of myeloma cells. Ann. Hematol. 1992; 6: 132 139.
- 34 Borowitz MJ, Guenther KL, Shults KE, Stelzer GT. Immunophenotyping of acute leukemia by flow cytometric analysis. Hematopathology 1993; 5: 534 540.
- 35 Maurer D, Felzmann T, Knapp W. A single laser flow cytometry method to evaluate the binding of three antibodies. J. Immunol. Meth 1990; 135: 43 47.
Citing Literature
